Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume Sells 4,400 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $163.11 on Friday. The stock’s 50-day simple moving average is $172.84 and its two-hundred day simple moving average is $188.09. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a P/E/G ratio of 4.54 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the business earned $2.46 EPS. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CRL shares. Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Robert W. Baird decreased their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday. UBS Group reiterated a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. The Goldman Sachs Group decreased their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Finally, Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $195.71.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Empirical Finance LLC boosted its holdings in shares of Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after purchasing an additional 53 shares in the last quarter. Fiduciary Financial Group LLC boosted its holdings in shares of Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. M&T Bank Corp boosted its holdings in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after purchasing an additional 66 shares in the last quarter. Finally, Cornerstone Investment Partners LLC boosted its holdings in Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after acquiring an additional 69 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).